Balloon Angioplasty
News from TCT: VOYAGER PAD and paclitaxel, STEMI in COVID-19 and more
Healio and Cardiology Today have curated a list of articles from the virtual TCT Connect.
ILLUMENATE Global: DCB safe, effective in real-world cohort at 4 years
A low-dose paclitaxel-coated balloon was safe and effective at 4 years in real-world patients with peripheral artery disease, according to the ILLUMENATE Global results presented at the virtual TCT Connect.
SCAI advises on optimal device use in aortoiliac interventions
The Society for Cardiovascular Angiography and Interventions released guidelines on selection of devices for aortoiliac arterial interventions.
Transradial access does not delay door-to-balloon times in STEMI PCI
The increasing use of transradial access for PCI over time did not compromise door-to-balloon times in patients with STEMI requiring PCI, according to new findings.
Endovascular treatment with standard care improved outcomes for basilar artery occlusion
Patients with acute basilar artery occlusion who were administered endovascular treatment within 24 hours of an estimated occlusion time had better functional outcomes and reduced mortality, according to data presented at the International Stroke Conference.
No 5-year mortality signal in trial of PCB for below-the-knee lesions
A paclitaxel-coated balloon was not associated with elevated mortality risk in patients who underwent revascularization for critical limb ischemia, according to 5-year data from the IN.PACT DEEP trial.
PCB for below-the-knee lesions does not confer long-term safety concern
A paclitaxel-coated balloon for treatment of below-the-knee lesions was not associated with excess mortality or amputation risk at 3 years, researchers reported at the Leipzig Interventional Course.
ILLUMENATE: DCB effective at 4 years with no mortality hazard
A paclitaxel-coated balloon was safe and effective in patients with peripheral artery disease at 4 years and did not confer elevated mortality risk compared with percutaneous transluminal angioplasty, according to new data from the ILLUMENATE Pivotal trial.
Meta-analysis of paclitaxel-coated balloons in CLI ‘should have no meaningful impact’
A recent meta-analysis detecting a signal of harm at 1 year in patients with below-the-knee lesions treated with paclitaxel-coated balloons is flawed and should not impact clinical practice, a speaker said at the International Symposium on Endovascular Therapy.
FRANCE-TAVI: In retrospective study, balloon-expandable TAVR valves safer than self-expanding
PHILADELPHIA — Balloon-expandable transcatheter aortic valves were associated with less paravalvular regurgitation and mortality compared with self-expanding valves, according to the FRANCE-TAVI retrospective study presented at the American Heart Association Scientific Sessions.